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Abstract
Introduction: The incidence of Frontotemporal Lobar Degeneration (FTLD)–related
disorders and their characteristics are not well known. The “FRONTotemporal demen-
tia Incidence European Research Study” (FRONTIERS) is designed to fill this gap.
Methods: FRONTIERS is a European prospective, observational population study
based on multinational registries. FRONTIERS comprises 11 tertiary referral centers
across Europewith long-lasting experience in FTLD-related disorders and comprehen-
sive regional referral networks, enabling incidence estimation over well-defined geo-
graphical areas.
Endpoints: The primary endpoints are (1) the incidence of FTLD-related disorders
across Europe; (2) geographic trends of FTLD-related disorders; (3) the distribution of
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FTLD phenotypes in different populations and ethnicities in Europe; (4) inheritance of
FTLD-related disorders, including the frequencies of monogenic FTLD as compared to
overall disease burden; and (5) implementation of data banking for clinical and biologi-
cal material.
Expected impacts: FRONTIERSwill improve the understanding of FTLD-related disor-
ders and their epidemiology, promoting appropriate public health service policies and
treatment strategies.
KEYWORDS
epidemiology, frontotemporal dementia, frontotemporal lobar degeneration, incidence, rare dis-
eases, registry
1 INTRODUCTION
Frontotemporal lobar degeneration (FTLD) encompasses a spectrum
of focal neurodegenerative diseases with progressive atrophy of the
frontal and temporal lobes.1–3 FTLD-related disorders are heteroge-
neous clinical conditions, characterized by social dysfunctions and per-
sonality change along with impairment in language, executive, and
motor functions.4 Current clinical diagnostic criteria characterize spe-
cific presentations of FTLD, including the behavioral variant fron-
totemporal dementia (bvFTD)5 and the primary progressive aphasias,
with the agrammatic variant (avPPA) and semantic variant (svPPA)
subtypes.6 Progressive supranuclear palsy (PSP)7 corticobasal syn-
drome (CBS),8 and FTD with amyotrophic lateral sclerosis (FTD-
ALS) are also usually caused by subtypes of FTLD. There is limited
correlation between these clinical syndromes and neuropathologi-
cal features.9 The neuropathological signature is associated mainly
with either tau or transactive response (TAR)-DNA-binding protein-43
(TDP-43) protein inclusions.10 Despite limited clinicopathological cor-
relations, some types of FTLD have a strong genetic background. Up to
≈30% of FTD patients have positive family history, with mutations in
the chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN), or
microtubule-associated protein tau (MAPT) genes each accounting for 5%
to 10% of patients.11
In the last 10 years, in depth clinical characterization of FTLD-
associated features improved and operationalized clinical diagnostic
criteria, and the use of biomarkers aimed at excluding Alzheimer’s dis-
ease (AD),12 have prompted a wider recognition of the diseases in clin-
ical settings. This in turn increases the estimated incidence. However,
epidemiological studies assessing the FTLD-related disorders overall
incidence and the relative frequency of the different phenotypes in the
general population are scarce, with marked variation in results.13–21
This variation can be attributed in part to narrow disease-specific and
phenotype based focus of individual studies; restriction to different
age-delimited sections of the population; and use of historical diag-
nostic criteria (before current consensus guidelines for each FTLD-
related disorder). Data on genetic correlates in different population-
representative cohorts remain sparse.
The FTLD-related disorders are individually relatively rare, and so
accurate epidemiological studies require surveillance of large popula-
tionswith a registry-based approach. This has been effective in theALS
field.22–25 A recent Italian retrospective research registry (the Salento-
Brescia registry) aimed to assess the incidence of different FTLD phe-
notypes in the general population, demonstrating that FTLD-related
disorders are more common than previously recognized. There was a
progressive increase in FTLD incidence across age groups, reaching its
peak in individuals older than 70 years of age.26 Comparable results
have been provided in a survey study conducted with similar method-
ology in the UK.15
Improved knowledge of FTLD-related disorders and their epidemi-
ology will help to promote appropriate public health service policies
and treatment approaches.We have established the FRONTotemporal
dementia Incidence European Research Study (FRONTIERS) as a col-
laborative European research initiative to assess FTLD epidemiology
across Europe, aligning prospective multinational disease population-
based disease registries.
1.1 Rationale of FRONTIERS
The rationale of FRONTIERS is to assess the epidemiology of FTLD-
related disorders across Europe, resolving some of the current issues
in the field.
First, FTLDhas often been considered a presenile dementia.11 How-
ever, it is clear that FTLD should not be confined exclusively within the
early onset dementias, as peak incidence may well be above 65 years,
andmay continue to rise if case ascertainment were complete. Second,
the distribution of clinical phenotypes in the general population is not
yet known. Estimates are based on clinical series from tertiary refer-
ral centers, which are liable to be biased and nonrepresentative. Third,
the distribution of monogenic FTLD-related disorders in Europe has
been deduced by ad hoc observational studies, with C9orf72 expansion
being more prevalent in Northern Europe, whereasGRN is in Southern
Europe, in areas like Northern Italy and Basque Country.27 However,
unbiased estimates of the incidence of monogenic FTLD causes disor-
ders have not yet been established.
To address these issues, a population-based approach through
multinational registries has several advantages: (1) in each registry
there is a prospective ascertainment of cases, seeking to minimize
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missing cases; (2) registries are generated from multiple sources of
case ascertainment; (3) there is a continuous surveillance of the
disease; and (4) matching diagnostic work-up and diagnostic criteria
are adopted.25
1.2 End points of FRONTIERS
The primary aims of FRONTIERS are (1) to assess the incidence of
FTLD-related disorders across Europe, considering presenile andmore
advanced age groups; (2) to assess the geographic distribution of
the disease; (3) to describe the distribution of FTLD phenotypes and
their heterogeneity in different populations anddifferent ancestral ori-
gins in Europe; (4) to define FTLD-related disorders inheritance, and
the frequencies of monogenic FTLD-related disorders across Europe,
including but not limited to the most frequent causes (ie., mutations
within GRN,MAPT, and C9orf72 genes); (5) to implement data banking
for clinical and biological material.
2 METHODS
2.1 Setting
FRONTIERS was established in February 6-7, 2020 at a consensus
meeting in Tricase, Italy. It was established with 11 centers across
Europe, each with long-lasting experience in the FTLD field and with
the ability to cover a well-defined geographical area. The pre-requisite
of a population-based registry is the correct definition of the popu-
lation at risk and the identification of proper sources of cases (see
Figure 1 and Table 1 for centers and Principal Investigators).
2.2 Participants and protocols
Patients with a new FTLD-related diagnosis in the defined ascertain-
ment time window and in the defined geographical boundaries will
be considered in FRONTIERS. The diagnosis will be made accord-
ing to current clinical criteria and supportive features for bvFTD,
PPA (semantic and agrammatic variants), PSP, CBS, and FTD-ALS
diagnoses.5–8 FRONTIERS will consider mixed or indeterminate PPA
with negative AD markers, but will not consider the logopenic
variant of PPA, as the majority of logopenic PPA cases have AD
pathology. Moreover, FRONTIERS will not include patients in their
prodromal stage and asymptomatic subjects carrying pathogenetic
mutations, and FRONTIERSwill not consider prevalent cases.
FRONTIERS participants will be assessed with a set of clinical, neu-
ropsychological, imaging and biomarkers protocols, according to stan-
dard diagnostics in each participating center, following which diagnos-
tic criteria of one of the FTLD phenotypes will be fulfilled as reported
above.5–8 A standardized set of data will be considered and recorded
by each center, including demographic characteristics and clinical fea-
tures, lifestyle and family history data, genetic screening results, and
biomarkers testing.
RESEARCH INCONTEXT
1. Systematic Review: Frontotemporal lobar degeneration
(FTLD) is the second most common cause of early
onset dementias. However, studies assessing the inci-
dence of clinically manifest FTLD-related disorders and
the related clinical and genetic features are still lim-
ited. The “FRONTotemporal dementia Incidence Euro-
peanResearch Study” (FRONTIERS) is designed to fill this
gap.
2. Interpretation: FRONTIERS will allow us to deter-
mine the epidemiology of FTLD-related disorders across
Europe as well as the distribution of clinical pheno-
types and genotypes. Furthermore, FRONTIERS will rep-
resent a source of cases for pragmatic trials and analytic
population-based studies, as well as a population-based
biobanking.
3. Future Directions: FRONTIERS will improve the under-
standing of FTLD-related disorders and their epidemiol-
ogy, promoting appropriate public health service policies
and treatment strategies.
Inclusion criteria will be the followings: (1) ≥18-years-old; (2) par-
ticipants must fulfill current clinical criteria of FTD, PSP, or CBS5–8; (3)
diagnosis of the FTLD-related disorder must be made in the referral
period of time of the current prospective study; (4) participants must
be living in the referral geographical area selected in each country for
the purpose of the present study; and (5) participants must have an
identified informant if necessary.
Exclusion criteria will be the followings: other medical or psy-
chiatric illness that would interfere in completing assessments/
diagnosis.
To minimize missing cases, the facilities of the referral geographical
area, lay local associations, and charities involved in dementia care will
be contacted by each center.
2.3 Demographic, clinical, and biomarkers data
collection
Place of birth and residence as well as date of FTLD-related disorders
diagnosis will be recorded. We will consider age, age at disease onset,
sex, clinical phenotype, the onset of symptoms, and disease duration
(in the recall of the patient or family). Age at onset will be defined as
the age at which first symptoms consistent with FTLD were observed
by patients or caregivers. Years of full-time education and occupation
attainmentwill be also recorded. Family history for neurodegenerative
dementias, ALS, or parkinsonism will be assessed by using a standard-
ized family history questionnaire.28
A standardized recording of extrapyramidal signs or motor neu-
ron disease will be carried out. Disease severity at diagnosis will be
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assessed by the Clinical Dementia Rating plus NACC,FTLD,29 and with
the PSP-Rating Scale (PSPRS)30 or theCortico Basal ganglia Functional
Scale,(CBFS),31 when appropriate.
Additional instrumental evaluations aimed at accomplishing a diag-
nosiswill be recorded. In particular,wewill consider cerebrospinal fluid
(CSF) markers (tau, phospho-tau and amyloid beta [Aβ]42 and Aβ40
dosage levels) or positron emission tomography (PET) amyloid scan,
to exclude AD, and PET-tau tracer or brain PET– fluorodeoxyglucose
(FDG) scan. For each of these markers, the result will be recorded as
“supporting FTLDdiagnosis,” “uninformative,” or “not supporting FTLD
diagnosis.”Wewill also record FTLDmimickers, namely, those subjects
fulfilling FTLD criteria but with positive AD biomarkers and likely with
mixed pathologies, especially in the older group, to determine their
incidence in population-based setting.
Finally, we will additionally measure neurofilament light in plasma
and CSF in FTLD patients.32
2.4 Genetic testing and sample biobanking
Each patient will undergo blood sampling for genetic screening
and biobanking. The most frequent monogenic causes are C9orf72,
MAPT, and GRN pathogenetic mutations. These will be assessed
locally, according to standard procedures.27 Where the genetic test-
ing is locally unavailable, genetic analyses will be provided by
other centers in the network. Biological samples, namely DNA,
plasma, and serum, will be stored locally for additional future anal-
yses, such as genome-wide association studies or exome sequenc-
ing analyses. CSF storage for future analyses will be considered
optional.
2.5 Data handling and record keeping
Data will be pseudo-anonymized, and each participant will be assigned
a unique investigation number (progressive number—country code),
and the patient identity will be accessible only to the referral center
where the data is acquired. Web-based data acquisition will be carried
out.
2.6 Ethical and regulatory considerations
The study will be performed on the basis of International Confer-
ence on Harmonisation/WHO (World Health Organization) Good
Clinical Practice (ICH-GCP) standards (www.ema.europa.eu/en/
ich-e6-r2-good-clinical-practice). Ethical approval for the study will
be obtained from the coordinating center and from each local ethical
review committees. Informed consent will cover participation in all
the aspects of the study, except where a participant has lost the
mental capacity to consent, in which case site-specific national laws
will be followed regarding the procedures to include legal incapacity
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TABLE 1 Centers and reference geographical area
Country Center
Principal
investigator(s) Reference geographical area
Reference
population
Italy Center for Neurodegenerative Disease
and the Aging Brain, University of Bari
Giancarlo
Logroscino
Salento area (Lecce province) 795,134a
Italy Centre for Neurodegenerative Disorders,
University of Brescia
Barbara Borroni Brescia province 1,265,954b
Sweden Karolinska University Hospital and
Institutet, Stockholm
Caroline Graff Stockholm area (Huddinge site) 967,160c
Bulgaria Department of Neurology, University
Hospital Alexandrovska, Sofia
Latchezar Traykov Sofia region 1,557,161d
Spain Neurology Department, Hospital
Universitario Donostia
FerminMoreno Donostialdea area (Basque
Country)
388,142e
Germany Neurology, University Hospital of Uhlm MarkusOtto,
Albert C. Ludolph
Ulm/Neu-Ulm area 184,711f
UK Centre for Frontotemporal Dementia and
related disorders, Cambridge University
James Rowe East England 1,753,964g
Finland Oulu University Hospital Anne Remes NorthernOsthrobothnia, Oulu
andNorthern Savonia, Kuopio
657,763h
Netherlands Alzheimer Center, Erasmus, Rotterdam Harro Seelaar Zuid-Holland 3,673,893i
Serbia Neurology, University of Belgrade Elka Stefanova Belgrade area 1,690,193j
Ireland Neurology, Trinity College, Dublin Orla Hardiman Dublin province 1,904,806k















participants in research. Data transfer agreements will be introduced
for transfer of clinical data and biosamples.
2.7 FRONTIERS lifespan, data access and
publication policy
FRONTIERS will have a duration of 3 years from the starting date,
which will be the same across the sites; a first end point will occur at
12months and a second end point will be set at 24months for prelimi-
nary analyses. An extension of study durationmay be considered.
Each PI will have access to anonymized data, and formal requests
for either data analyses or biological samples will be submitted in writ-
ing to the other PIs, along with a brief description of the project that
includes specific aims, study design, and characteristics of the data
requested. The data request will be reviewed by the PIs and approved.
Publication policy agreement has already been defined and articles
will list as authors all PIs and all other researchers who have made a
scientific and/or clinical contribution. Co-investigators will be quoted
under a final corporate author reflecting the FRONTIERS collabora-
tion.
2.8 Statistics
The following sets of variables will be recorded: (1) demographic data;
(2) family history; (3) clinical phenotype; and (4) genetic mutations.
Overall, FRONTIERS will cover defined geographical areas of inter-
est across 10 European Countries (see Table 1), with a total estimated
overall population of about 15 million people. In a first step, incidence
rates will be computed separately for each region. The numerator of
each rate will be the number of cases from the region, collected by
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each center during the study period. The denominator of each rate
(person-years spent at risk during the study period) will be estimated
using the information on the number of residents living in the covered
geographic area at a specific time point.33 Age-sex standardized inci-
dence rates will be also computed using the European population as
standard. Heterogeneity of incidence rate estimates across geographi-
cal regionswill be assessed. In a second step, results fromdifferent geo-
graphical regions will be combined using methods to properly account
for between-region variability such asmixed-effectmodels,34 to obtain
a European summary incidence estimate.
3 EXPECTED RESULTS AND IMPACT
Registries are powerful tools to develop clinical research, to improve
patients care by appropriate planning of public policies for health care
and to facilitate the correct design for clinical trials.25 This is par-
ticularly true in case of relatively rare neurodegenerative disorders,
characterized by clinical complexity and heterogeneity as well as low
incidence and prevalence. In this setting, population-based registries
represent the only cost-effective way to estimate the incidence of a
disease.25,26 Assessing disease incidence and studying how the fre-
quency changes over time in a given geographical area and among sub-
groups are crucial in epidemiology tounderstanddisease causation and
to investigate possible risk factors.35
FRONTIERS, a multinational prospective population-based reg-
istry, will provide multi-source case ascertainment and will allow the
description of FTLD-related phenotypes across Europe as well as the
distribution of causative genetic traits.Wewill work with other cohort
studies of related disorders, including the Genetic Frontotemporal
Dementia Initiative (GENFI; seven FRONTIERS sites are members of
GENFI consortium), and UK, German and Italian research cohorts for
PSP and CBS (ie., PROgressive Supranuclear Palsy Cortico-Basal Syn-
drome, PROSPECT study), FTLD consortium (www.ftld.de), Treatment
Research Initiative to Cure ALS, TRICALS Consortium for ALS.
FRONTIERS will represent a source of cases for pragmatic trials
and analytic population-based studies, as well as a population-based
biobanking. A major impact of FRONTIERS will be an accurate under-
standing of epidemiology of FTLD-related disorders, to answer a broad
range of questions: (1) Are FTLD-related disorders common? (2) Is inci-
dence of FTLD-related disorders comparable across European ances-
tral populations and countries? (3) Should FTLD-related disorders be
consideredadisorder ofmidlife? (4) Is bvFTDmore common thanPPAs,
or vice versa? (5) Are FTLD-related disorders associated with specific
risk factors? (6) Is distribution of FTLD-related disorders comparable
across Europe? (7)Which is the impact ofmonogenic FTLD to the over-
all burdenofdisease? (8) Is distributionofmonogenicFTLD-relateddis-
orders comparable across ethnicities/countries? (9)What are the char-
acteristics of the diagnostic journey for FTLD-related disorders? (10)
Canwe confirm suggestions for the staging of FTLD, both neuropatho-
logically and clinically?.36,37
FRONTIERS will be equipped to address these questions, as the
study is population based, and all the new cases in a defined period of
time and in a defined geographical area will be collected for compre-
hensive analysis of demographics, phenotypes, and outcomes across
different geographic regions.25
FRONTIERS will allow us to determine the distribution of clini-
cal phenotypes and genotypes, as well as the relative weight of each
in each country in Europe. Moreover, we seek new insights into the
spreading of FTLD-relatedmutations throughout Europe.38
High quality data of registries and near-completeness of case ascer-
tainment is one of key elements to obtain reliable data. FRONTIERS
will attempt to minimize misclassification biases with the inclusion of
tertiary referral centers with long-lasting experiences in FTLD diagno-
sis, with the rigorous definition of geographic boundaries of areas of
interest, with the standardization of diagnostic and inclusion/exclusion
criteria, and with the implementation of effective case identification
strategies by referrals through networks of clinical professionals and
charities. Furthermore, if suitable sources like administrative data are
available, we are going to implement capture-recapture analyses to
estimate the rate ofmissing cases,39 as previously has been succesfully
done in ALS.40 An important effort will be devoted to the harmoniza-
tion of data among centers with periodic meetings with special focus
on diagnosis of different phenotypes.
We recognize that this project does not involve systematic collec-
tion and storage of CSF and brain tissue, thus representing a limita-
tion to the study.Moreover, assessment of biologicalmarkers that have
recently aroused interest in the FTLD field have not been included in
theFRONTIERSprimaryoutcomes; however, additional studiesmaybe
carried out in the next future on stored biosamples.
Finally, we acknowledge that population-based registers require a
number of years of activity to ensure that early biases are resolved; this
is generally a bias toward enrollment of prevalent cases, wrongly clas-
sified as incident within the first year of the study.25
In conclusion, FRONTIERS will be a unique contribution to the
field, primarily in the area of epidemiology, and will allow improv-
ing our understanding of clinical and biological FTLD heterogeneity
within and across different populations,whichmayhelp to guide future
regulatory policies and clinical decision-making. FRONTIERS will be
an exceptional platform to develop new pharmacological and non-
pharmacological trials.
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